ESR1 and breast carcinoma: A phase II trial (NCT00468715) is currently investigating the effectiveness of bicaluamide in ER negative, AR positive breast cancer and a recent study found that AR expression is associated with a favorable prognosis subgroup of chemoresistant TNBC tumors [29].